## Contents

**EDITORIAL**

1549  Multidisciplinary approach toward enhanced recovery after surgery for total knee arthroplasty improves outcomes

*Nag DS, Swain A, Sahu S, Sahoo A, Wadhwa G*

1555  Using clinical cases to guide healthcare

*Colwill M, Baillie S, Pollok R, Poullis A*

---

**ORIGINAL ARTICLE**

**Retrospective Study**

1560  Analysis of the causes of primary revision after unicompartmental knee arthroplasty: A case series

*Zhao JL, Jin X, Huang HT, Yang WY, Li JH, Luo MH, Liu J, Pan JK*

1569  Efficacy and safety of minimally invasive laparoscopic surgery under general anesthesia for ovarian cancer

*Qin X, Chen C, Liu Y, Hua XH, Li JY, Liang MJ, Wu F*

1578  Factors influencing Frey syndrome after parotidectomy with acellular dermal matrix

*Chai XD, Jiang H, Tang LL, Zhang J, Yue LF*

**Clinical Trials Study**

1585  Allogeneic mesenchymal stem cells may be a viable treatment modality in cerebral palsy

*Boyalı O, Kabatas S, Civelek E, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E*

**Observational Study**

1597  Clinical characteristics of acute non-varicose upper gastrointestinal bleeding and the effect of endoscopic hemostasis

*Wang XJ, Shi YP, Wang L, Li YN, Xu LJ, Zhang Y, Han S*

**Clinical and Translational Research**

1606  Construction of the underlying circRNA-miRNA-mRNA regulatory network and a new diagnostic model in ulcerative colitis by bioinformatics analysis

*Yuan YY, Wu H, Chen QY, Fan H, Shuai B*

1622  Exploring the autophagy-related pathogenesis of active ulcerative colitis

*Gong ZZ, Li T, Yan H, Xu MH, Lian Y, Yang YX, Wei W, Liu T*

---

**CASE REPORT**

1634  Low-molecular-weight heparin and preeclampsia — does the sword cut both ways? Three case reports and review of literature

*Shan D, Li T, Tan X, Hu YY*
Contents

1644  Pulmonary alveolar proteinosis induced by X-linked agammaglobulinemia: A case report
Zhang T, Li M, Tan L, Li X

1649  Gradient inflammation in the pancreatic stump after pancreaticoduodenectomy: Two case reports and review of literature
Wang TG, Tian L, Zhang XL, Zhang L, Zhao XL, Kong DS

1660  Low interleukin-10 level indicates a good prognosis in Salmonella enterica serovar typhimurium-induced pediatric hemophagocytic lymphohistiocytosis: A case report
Chen YY, Xu XZ, Xu XJ

1669  Multi-systemic melioidosis in a patient with type 2 diabetes in non-endemic areas: A case report and review of literature
Ni HY, Zhang Y, Huang DH, Zhou F

1677  Endoscopic ultrasound-guided tissue sampling induced pancreatic duct leak resolved by the placement of a pancreatic stent: A case report
Kim KH, Park CH, Cho E, Lee Y

1685  Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab: A case report
Xu X, Jiang JW, Lu BY, Li XX

1691  Exogenous insulin autoimmune syndrome: A case report and review of literature
Xu LL, Chen JX, Cheng JP, Luo N

1698  Unexplained fetal tachycardia: A case report
Wang H, Duan RZ, Bai XJ, Zhang BT, Wang J, Song WX

1704  Challenging anticoagulation therapy for multiple primary malignant tumors combined with thrombosis: A case report and review of literature
Chen JX, Xu LL, Cheng JP, Xu XH

LETTER TO THE EDITOR

1712  Epinephrine also acts on beta cells and insulin secretion
Zabuliene L, Ilias I
ABOUT COVER
Peer Reviewer of World Journal of Clinical Cases, Luca Mezzetto, MD, Surgeon, Department of Vascular Surgery, University Hospital of Verona, Verona 37126, Italy. luca.mezzetto@aovr.veneto.it

AIMS AND SCOPE
The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING
The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Reference Citation Analysis, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 Edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJCC as 1.1; IF without journal self cites: 1.1; 5-year IF: 1.3; Journal Citation Indicator: 0.26; Ranking: 133 among 167 journals in medicine, general and internal; and Quartile category: Q4.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Zi-Hang Xu; Production Department Director: Xiang Li; Cover Editor: Jin-Lei Wang.

NAME OF JOURNAL
World Journal of Clinical Cases

ISSN
ISSN 2307-8960 (online)

LAUNCH DATE
April 16, 2013

FREQUENCY
Thrice Monthly

EDITORS-IN-CHIEF
Bao-Gan Peng, Salim Surani, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati

EDITORIAL BOARD MEMBERS
https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE
March 26, 2024

COPYRIGHT
© 2024 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS
https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS
https://www.wjgnet.com/bpg/gerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS
https://www.wjgnet.com/bpg/gerinfo/288

PUBLICATION MISCONDUCT
https://www.wjgnet.com/bpg/gerinfo/208

ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/bpg/gerinfo/242

STEPS FOR SUBMITTING MANUSCRIPTS
https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION
https://www.f6publishing.com
Low interleukin-10 level indicates a good prognosis in *Salmonella enterica* serovar typhimurium-induced pediatric hemophagocytic lymphohistiocytosis: A case report

Yuan-Yuan Chen, Xiang-Zhi Xu, Xiao-Jun Xu

**Abstract**

**BACKGROUND**

Secondary hemophagocytic lymphohistiocytosis (sHLH) triggered by *Salmonella enterica* serovar Typhimurium is rare in pediatric patients. There is no consensus on how to treat *S. typhimurium*-triggered sHLH.

**CASE SUMMARY**

A 9-year-old boy with intermittent fever for 3 d presented to our hospital with positive results for *S. typhimurium*, human rhinovirus, and *Mycoplasma pneumoniae* infections. At the time of admission to our institution, the patient’s T helper 1/T helper 2 cytokine levels were 326 pg/mL for interleukin 6 (IL-6), 9.1 pg/mL for IL-10, and 246.7 pg/mL for interferon-gamma (IFN-γ), for which the ratio of IL-10 to IFN-γ was 0.04. In this study, the patient received meropenem, linezolid, and cefoperazone/sulbactam in combination with high-dose methylprednisolone therapy (10 mg/kg/d for 3 d) and antishock supportive treatment twice. After careful evaluation, this patient did not receive HLH chemotherapy and recovered well.

**CONCLUSION**

*S. Typhimurium* infection-triggered sHLH patient had a ratio of IL-10 to IFN-γ ≤ 1.33, an IL-10 concentration ≤ 10.0 pg/mL, and/or an IFN-γ concentration ≤ 225 pg/mL at admission. Early antimicrobial and supportive treatment was sufficient, and the HLH-94/2004 protocol was not necessary under these conditions.

**Key Words:** Hemophagocytic lymphohistiocytosis; Cytokine pattern; Interferon gamma;
Chen YY et al. IL-10 level indicates prognosis in sHLH

Interleukin-10; Salmonella enterica serovar Typhimurium; Case report

©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Salmonella enterica serovar Typhimurium is one kind of pathogen that can trigger secondary hemophagocytic lymphohistiocytosis (sHLH). There is no consensus on how to treat S. Typhimurium-triggered sHLH. Compared to controls, an S. Typhimurium-triggered sHLH patient showed a ratio of interleukin-10 (IL-10) to interferon-gamma (IFN-γ) ≤ 1.33, an IL-10 concentration ≤ 10.0 pg/mL, and/or IFN-γ concentration ≤ 225 pg/mL on admission. The HLH-94/2004 protocol was not necessary, and early antimicrobial and supportive treatment was sufficient.

INTRODUCTION

Hemophagocytic lymphohistiocytosis (HLH) is a syndrome composed of clinical findings such as fever, hepatosplenomegaly, cytopenias, hypertriglyceridemia, hypofibrinogenemia, hemophagocytosis in the bone marrow or spleen or lymph nodes, low or absent natural killer cell activity, and elevated levels of serum ferritin (SF) and soluble cluster of differentiation 25 (CD25)[1]. HLH comprises two conditions: primary HLH (pHLH) and secondary HLH (sHLH). pHLH occurs in the presence of an underlying predisposing genetic defect in the cytolytic pathway, whereas sHLH is acquired in the setting of an infectious, malignant, or autoimmune cause without genetic defects[2]. sHLH can be triggered by the Epstein-Barr virus (EBV)[3], cytomegalovirus[4], and Salmonella enterica serovar typhimurium[5,6], etc. S. typhimurium is a Gram-negative bacterium that depends on an essential inflammatory response to colonize the intestinal tract, causing self-limiting gastroenteritis in humans[7,8]. S. typhimurium alone, in some animal models, could be an independent trigger of sHLH[9]. Some pediatric patients infected with S. typhimurium progress to sHLH[10]. Cytokine storm syndrome is a life-threatening systemic inflammatory state characterized by elevated levels of circulating cytokines and immune cell hyperactivation[11]. In our previous study, we reported a specific cytokine pattern for HLH: interleukin 10 (IL-10) > 60 pg/mL, interferon gamma (IFN-γ) > 75 pg/mL, and IL-6 > 51.1 pg/mL[12]. Patients with a ratio of IL-10 to IFN-γ > 1.33 combined with IFN-γ ≤ 225 pg/mL were considered to have pHLH, whereas sHLH patients usually had a ratio of IL-10 to IFN-γ ≤ 1.33[13]. Moreover, an IL-10 concentration ≥ 456 pg/mL was an independent prognostic factor for early death[14].

In this study, a patient who developed HLH due to S. typhimurium infection is described. His IL-10 concentration was 9.1 pg/mL, and the ratio of IL-10 to IFN-γ was 0.04 at admission. Seven patients infected with S. typhimurium and three EBV-HLH patients were included as controls. The HLH patient did not receive chemotherapy, and after anti-infection therapy and supportive treatments, he recovered very well.

CASE PRESENTATION

Chief complaints
A 9-year-old Chinese boy was admitted to the hospital due to an intermittent fever for 3 d.

History of present illness
Approximately 3 d before admission, the patient presented with a fever of 39.3 °C without any inductive or provocative factors, and his complete blood count (CBC) showed pancytopenia. His white blood cell count was 2.33 × 10^9/L, his hemoglobin level was 96 g/L, and his platelet was 25 × 10^9/L. He did not have any symptoms of cough, vomiting, or diarrhea.

History of past illness
The patient had no relevant medical history.

Personal and family history
There were no special features in the patient's background or family history, and there was no consanguinity.

Physical examination
At the time of admission, the patient had an intermittent fever for 3 d. His abdomen was distended, and there was no
enlargement of the spleen or liver below his costal margins. No palpable lymphadenopathy was observed. Physiological reflexes were normal. The Bacillus Calmette-Guerin vaccination scar was normal, and no rashes were observed on his skin. The vital signs of the patient during hospitalization are shown in Table 1.

**Laboratory examinations**

His soluble CD25 concentration was 2646.9 pg/mL. Bone marrow biopsy revealed some hemophagocytic histiocytes and a decreased number of megakaryocytes. T helper 1/T helper 2 (Th1/Th2) cytokine levels, including those of IL-2, IL-4, IL-6, IL-10, tumor necrosis factor-alpha (TNF-α), and IFN-γ, were quantitatively determined with a human Th1/Th2 Cytokine Kit II (BD Biosciences, San Jose, CA, United States) during the course of the disease (Figures 1 and 2). The results of the CBC comparison (Figure 3), C-reactive protein, procalcitonin, fibrinogen, triglyceride, and SF levels are shown in Table 1. The other laboratory findings are shown in Table 2.

**Imaging examinations**

B-ultrasound of the abdomen and chest computed tomography showed no abnormalities.

**FINAL DIAGNOSIS**

The final diagnosis was sHLH due to *S. typhimurium* infection. The diagnosis of HLH was established on the basis of fever, cytopenia, hypofibrinogenemia, and hemophagocytosis in the bone marrow; elevated levels of SF; and increased soluble CD25, which fulfilled more than five criteria. The diagnosis of *S. typhimurium* infection was confirmed by blood culture.
## Table 1 Clinical indexes from admission to discharge

<table>
<thead>
<tr>
<th>Testing date</th>
<th>WBC as × 10^9/L</th>
<th>ALC as × 10^9/L</th>
<th>ANC as × 10^9/L</th>
<th>Hb in g/L</th>
<th>PLT as × 10^9/L</th>
<th>CRP in mg/L</th>
<th>PCT in ng/mL</th>
<th>Fib in g/L</th>
<th>TG in mmol/L</th>
<th>SF in mg/L</th>
<th>T in C</th>
<th>HR, times/min</th>
<th>RR, times/min</th>
<th>BP in mmHg</th>
<th>SpO2, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 25, 2022</td>
<td>2.33</td>
<td>0.57</td>
<td>1.63</td>
<td>96</td>
<td>25</td>
<td>10.88</td>
<td>2.32</td>
<td>2.23</td>
<td>1.03</td>
<td>&gt; 1500</td>
<td>39.4</td>
<td>128</td>
<td>20</td>
<td>78/40</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>September 26, 2022</td>
<td>2.74</td>
<td>0.83</td>
<td>1.8</td>
<td>109</td>
<td>36</td>
<td>11.52</td>
<td>2.8</td>
<td>1.93</td>
<td>1.39</td>
<td>&gt; 1500</td>
<td>35.6</td>
<td>16</td>
<td>30</td>
<td>91/70</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>September 27, 2022</td>
<td>2.75</td>
<td>0.76</td>
<td>1.91</td>
<td>98</td>
<td>26</td>
<td>6.2</td>
<td>2.6</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>35.5</td>
<td>78</td>
<td>20</td>
<td>105/67</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>September 28, 2022</td>
<td>2.14</td>
<td>0.82</td>
<td>1.2</td>
<td>87</td>
<td>76</td>
<td>2.69</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>1835.0</td>
<td>74</td>
<td>18</td>
<td>105/73</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>September 29, 2022</td>
<td>2.51</td>
<td>1.08</td>
<td>1.23</td>
<td>89</td>
<td>70</td>
<td>1.01</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>36.0</td>
<td>77</td>
<td>19</td>
<td>100/75</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>September 30, 2022</td>
<td>2.81</td>
<td>0.97</td>
<td>1.71</td>
<td>92</td>
<td>58</td>
<td>0.48</td>
<td>NT</td>
<td>NT</td>
<td>1.12</td>
<td>1.7</td>
<td>NT</td>
<td>36.0</td>
<td>102</td>
<td>18</td>
<td>83/54</td>
</tr>
<tr>
<td>October 2, 2022</td>
<td>4.82</td>
<td>3.03</td>
<td>1.58</td>
<td>87</td>
<td>37</td>
<td>0.64</td>
<td>NT</td>
<td>NT</td>
<td>1.59</td>
<td>NT</td>
<td>725.2</td>
<td>37.3</td>
<td>86</td>
<td>20</td>
<td>86/60</td>
</tr>
<tr>
<td>October 3, 2022</td>
<td>3.93</td>
<td>2.23</td>
<td>1.63</td>
<td>81</td>
<td>38</td>
<td>0.38</td>
<td>0.291</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>37.1</td>
<td>72</td>
<td>22</td>
<td>72/44</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>October 4, 2022</td>
<td>6.31</td>
<td>4.73</td>
<td>1.35</td>
<td>84</td>
<td>29</td>
<td>0.5</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>38.4</td>
<td>123</td>
<td>23</td>
<td>90/58</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>October 5, 2022</td>
<td>4.11</td>
<td>2.72</td>
<td>1.19</td>
<td>77</td>
<td>31</td>
<td>0.87</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>37.9</td>
<td>112</td>
<td>22</td>
<td>82/57</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>October 6, 2022</td>
<td>4.04</td>
<td>2.94</td>
<td>0.94</td>
<td>74</td>
<td>50</td>
<td>1.1</td>
<td>0.118</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>38.6</td>
<td>154</td>
<td>28</td>
<td>87/56</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>October 7, 2022</td>
<td>3.67</td>
<td>2.78</td>
<td>0.68</td>
<td>77</td>
<td>50</td>
<td>1.79</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>37.8</td>
<td>120</td>
<td>16</td>
<td>97/69</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>October 8, 2022</td>
<td>3.73</td>
<td>2.99</td>
<td>0.55</td>
<td>75</td>
<td>50</td>
<td>1.37</td>
<td>NT</td>
<td>NT</td>
<td>3.44</td>
<td>NT</td>
<td>384.5</td>
<td>37.6</td>
<td>136</td>
<td>22</td>
<td>75/51</td>
</tr>
<tr>
<td>October 9, 2022</td>
<td>3.53</td>
<td>2.36</td>
<td>0.92</td>
<td>105</td>
<td>50</td>
<td>0.92</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>37.6</td>
<td>105</td>
<td>23</td>
<td>108/76</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>October 10, 2022</td>
<td>3.98</td>
<td>3.05</td>
<td>0.69</td>
<td>93</td>
<td>48</td>
<td>0.9</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>332.5</td>
<td>37.6</td>
<td>95</td>
<td>24</td>
<td>111/77</td>
</tr>
<tr>
<td>October 11, 2022</td>
<td>4.78</td>
<td>3.64</td>
<td>0.88</td>
<td>99</td>
<td>56</td>
<td>1.3</td>
<td>0.096</td>
<td>NT</td>
<td>NT</td>
<td>NT</td>
<td>37.3</td>
<td>131</td>
<td>20</td>
<td>128/84</td>
<td>&gt; 95%</td>
</tr>
<tr>
<td>October 12, 2022</td>
<td>5.89</td>
<td>4.78</td>
<td>0.73</td>
<td>98</td>
<td>54</td>
<td>1.08</td>
<td>NT</td>
<td>NT</td>
<td>1.11</td>
<td>NT</td>
<td>37.2</td>
<td>104</td>
<td>26</td>
<td>84/59</td>
<td>&gt; 95%</td>
</tr>
</tbody>
</table>
TREATMENT
From September 25, 2022 to September 26, 2022, this patient received meropenem and linezolid anti-infection therapy. From September 26, 2022 to September 28, 2022, the patient received meropenem and high-dose methylprednisolone therapy (180 mg/d, body weight of 18.8 kg). From September 28, 2022 to October 11, 2022, the patient received cefoperazone/sulbactam as anti-infection therapy, and *S. typhimurium* was sensitive to the treatment. During the inpatient period, this boy experienced two episodes of shock, one on September 25, 2022 and one on October 3, 2022, during which time his blood pressure decreased to 78/40 mmHg and 72/44 mmHg, respectively. Both episodes of shock occurred after the patient developed a fever, and his body temperature eventually returned to normal. After antishock therapy, his vital signs stabilized. From October 11, 2022 to October 17, 2022, this patient received meropenem therapy again.

OUTCOME AND FOLLOW-UP
After careful evaluation, the patient did not receive HLH chemotherapy during the whole disease course and was discharged on October 17, 2022. During the nonhospitalization period, he was followed up by telephone for more than 1 year and recovered very well.

DISCUSSION
Currently, dexamethasone, etoposide, cyclosporine A, and ruxolitinib are the main choices for HLH treatment[15]. Reliable laboratory markers that can differentiate subtypes of HLH at an early stage would provide tremendous help for treatment. Several researchers have shown that elevated IL-10 levels are associated with a poor prognosis in HLH[16,17]. In this study, we examined 8 children infected with *S. typhimurium*, and only 1 of them fulfilled the diagnostic criteria for HLH. The IL-10 levels in this *S. typhimurium*-HLH patient and the 7 controls with *S. typhimurium* infection were lower than 10.0 pg/mL, while the levels of IL-10 in the 3 EBV-HLH patients were all greater than 10.0 pg/mL. In our clinical practice, different cytokine patterns for differentiating various HLH subtypes can be obtained within 5 h, and 88 patients with IFN-γ levels ≤ 225 pg/mL and a ratio of IL-10 to IFN-γ ≤ 1.33 have the best outcome, showing that this subtype has
Figure 2 Four-quadrant models for differentiating secondary hemophagocytic lymphohistiocytosis patients with different features. A: Distribution of the patients, 7 controls infected with Salmonella enteric serovar typhimurium (S. typhimurium), and 3 Epstein-Barr virus-hemophagocytic lymphohistiocytosis (EBV-HLH) patients according to a four-quadrant diagram based on the ratio of interleukin-10 (IL-10) to interferon gamma (IFN-γ) > 1.33 or ≤ 1.33 and IFN-γ level > 225 pg/mL or ≤ 225 pg/mL; B: Distribution of the patients, 7 controls infected with S. typhimurium, and 3 EBV-HLH patients according to a four-quadrant diagram based on the ratio of IL-10 to IFN-γ > 1.33 or ≤ 1.33 and IL-10 level > 10 pg/mL or ≤ 10 pg/mL.

Figure 3 Complete blood count at admission and 5 d later. A: White blood cell (WBC) count of the patient, 7 Salmonella enteric serovar typhimurium (S. typhimurium)-infected controls, and 3 Epstein-Barr virus-hemophagocytic lymphohistiocytosis (EBV-HLH) controls; B: Absolute lymphocyte count (ALC) of the patient and controls; C: Absolute neutrophil count (ANC) of the patient and controls; D: Hemoglobin (Hb) of the patient and controls; E: Platelet (PLT) count of the patient and controls; F: C-reactive protein (CRP) of the patient and controls.
Table 2 Results of laboratory examinations after admission

<table>
<thead>
<tr>
<th>Testing date</th>
<th>Laboratory examination items</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>September 26, 2022</td>
<td>Nucleic acid detection of 13 pathogens from nasopharyngeal swab</td>
<td>Human Rhino Virus and Mycoplasma Pneumoniae were positive, and others were all negative</td>
</tr>
<tr>
<td>September 26, 2022</td>
<td>T-cell spot of tuberculosis assay</td>
<td>Negative</td>
</tr>
<tr>
<td>September 26, 2022</td>
<td>EBV antibodies</td>
<td>EBVCA-IgM was 1.26 U/mL, EBVCA-IgG was 10.9 U/mL, EBNA-IgG was more than 600 U/mL, EBEA-IgG was negative, and EBEA-IgM was 0.06 COI</td>
</tr>
<tr>
<td>September 26, 2022</td>
<td>EBV-DNA</td>
<td>0 copies/mL</td>
</tr>
<tr>
<td>September 28, 2022</td>
<td>Blood culture</td>
<td>S. typhimurium was positive</td>
</tr>
<tr>
<td>September 30, 2022</td>
<td>Widal test</td>
<td>FDSO, FDSH, FDSA, FDSB, and FDSC were all less than 1:40</td>
</tr>
<tr>
<td>October 1, 2022</td>
<td>Stool culture</td>
<td>Negative</td>
</tr>
<tr>
<td>October 1, 2022</td>
<td>Cerebrospinal fluid culture</td>
<td>Negative</td>
</tr>
<tr>
<td>October 4, 2022</td>
<td>Blood culture for the second time</td>
<td>Negative</td>
</tr>
<tr>
<td>October 7, 2022</td>
<td>Urine culture</td>
<td>Negative</td>
</tr>
<tr>
<td>October 7, 2022</td>
<td>Sputum culture</td>
<td>Negative</td>
</tr>
<tr>
<td>October 11, 2022</td>
<td>Bone marrow culture</td>
<td>Negative</td>
</tr>
<tr>
<td>October 17, 2022</td>
<td>Widal test for the second time</td>
<td>FDSO and FDSH were both 1:40, while FDSA, FDSB, and FDSC were less than 1:40</td>
</tr>
</tbody>
</table>

COI: Cut-off index; EBEA: EBV early antigen; EBNA: EBV nuclear antigen; EBV: Epstein-Barr virus; EBVCA: EBV viral capsid antigen; FDSB: Antigen of Salmonella paratyphi B; FDS: Antigen of Salmonella paratyphi C; FDSO: O-antigen of S. typhimurium; FDSH: H-antigen of S. typhimurium; FDSA: Antigen of Salmonella paratyphi A; IgG: Immunoglobulin G; IgM: Immunoglobulin M.

the best outcome of all HLH subtypes[13], which was verified by this study.

There is no consensus on how to treat S. typhimurium-triggered sHLH, and early intervention is needed to improve outcomes in patients with HLH[18]. Most of the current research is empirical, and the decision-making process is relevant to the time point at which positive culture results are obtained and based on the clinician’s experience. Several researchers have shown that antimicrobial and supportive treatment alone are effective[5,19-23]. However, many researchers have used both antimicrobial treatment and the HLH protocol to treat sHLH triggered by Salmonella infections[6,10,24]. In this study, after careful evaluation, our patient did not receive HLH chemotherapy during the whole disease course. After receiving meropenem, linezolid, and cefoperazone/sulbactam for anti-infection therapy combined with high-dose methylprednisolone therapy, the patient recovered very well.

This study had several limitations. First, it was impossible to precisely distinguish pHLH from sHLH, as this patient did not undergo pHLH-related gene examinations during the study period. Second, the 7 controls infected with S. typhimurium recovered well, and only some agreed to undergo a second recheck of their cytokines and CBC, which led to missing data. Finally, only 1 patient infected with S. typhimurium progressed to sHLH, and we could not perform a cohort analysis of specific cytokine patterns.

CONCLUSION

In summary, if a Salmonella-triggered sHLH patient has a ratio of IL-10 to IFN-γ ≤ 1.33, an IL-10 concentration ≤ 10.0 pg/mL, and/or an IFN-γ concentration ≤ 225 pg/mL at admission, early antimicrobial and supportive treatment may be sufficient. Eight weeks of dexamethasone treatment and the HLH-94/2004 protocol are not necessary under these conditions.

FOOTNOTES

Author contributions: Xu XJ was the principal investigator and takes primary responsibility for the manuscript; Chen YY and Xu XZ acquired and analyzed the data; Chen YY drafted the manuscript; Xu XJ and Chen YY revised the manuscript; All authors approved the final version to be published.

Supported by Zhejiang Province Health and Wellness Science and Technology Program in 2022, China, No. 2022RC202.

Informed consent statement: Written informed consent was obtained from the patient’s guardian for publication of this case report and
accompanying images.

**Conflict-of-interest statement:** The authors have no conflicts of interest to declare.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Country/Territory of origin:** China

**ORCID number:** Yuan-Yuan Chen 0000-0002-8206-1979; Xiang-Zhi Xu 0009-0004-1727-9068; Xiao-Jun Xu 0000-0003-1388-2535.

**S-Editor:** Liu H
**L-Editor:** Filipodia
**P-Editor:** Cai YX

---

**REFERENCES**


16. **Hao L**, Ren J, Zhu Y, Ma Y, Pan J, Yang L. Elevated Interleukin-10 Levels Are Associated with Low Platelet Count and Poor Prognosis in 90 Adult Patients with Hemophagocytic Lymphangiitis. *Int Arch Allergy Immunol* 2023; 184: 400-408 [PMID: 36634629 DOI: 10.1159/000528349]


Chen YY et al. IL-10 level indicates prognosis in sHLH


